Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Latozinemab (AL001) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about Latozinemab (AL001) for Frontotemporal dementia (FTD) in 7 major markets.
A detailed picture of the Latozinemab (AL001) for Frontotemporal dementia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Latozinemab (AL001) for Frontotemporal dementia.
The report provides insight about mechanism of action, dosage, and administration, as well as research and development activity including regulatory milestones, along with other developmental activities.
Further, it also consists of future market assessments inclusive of the Latozinemab (AL001) market forecast, analysis for Frontotemporal dementia in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Frontotemporal dementia.
Drug Summary
Latozinemab (AL001) is Alector's wholly-owned humanized recombinant monoclonal antibody designed to modulate progranulin - a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer's disease, and Parkinson's disease. It aims to increase the progranulin level in humans by inhibiting the progranulin degradation mechanism. AL001 is being developed in collaboration with GSK.
Latozinemab, which is administered via intravenous peripheral infusion, works by inhibiting the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of functional PGRN in the brain. It is being developed to treat FTD patients who have a heterozygous loss-of-function mutation in granulin (FTD-GRN). Latozinemab was initially intended for FTD-GRN patients, but the company has now begun a Phase II clinical trial for FTD-C9orf72 patients, as well as several other neurological indications such as Alzheimer's and Parkinson's disease.
FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43. The Phase II study, which includes participants with progranulin mutations (FTD-GRN), is intended to assess the safety and tolerability of chronic AL001 dosing. Treatment with latozinemab was estimated to slow disease progression by 48% in 12 patients at 12 months.
In-depth Latozinemab (AL001) Market Assessment
This report provides a detailed market assessment of Latozinemab (AL001) in Frontotemporal dementia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
Latozinemab (AL001) Clinical Assessment
The report provides the clinical trials information of Latozinemab (AL001) in Frontotemporal dementia covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions Answered
- What is the product type, route of administration and mechanism of action of Latozinemab (AL001)?
- What is the clinical trial status of the study related to Latozinemab (AL001) in Frontotemporal dementia and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Latozinemab (AL001) development?
- What are the key designations that have been granted to Latozinemab (AL001) for Frontotemporal dementia?
- What is the forecasted market scenario of Latozinemab (AL001) for Frontotemporal dementia?
- What are the forecasted sales of Latozinemab (AL001) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available in Frontotemporal dementia and how are they giving competition to Latozinemab (AL001) for Frontotemporal dementia?
- Which are the late-stage emerging therapies under development for the treatment of Frontotemporal dementia?
Key Topics Covered:
1 Report Introduction
2 Latozinemab (AL001) Overview
2.1 Product Detail
2.2 Clinical Development
2.2.1 Clinical Studies
2.2.2 Clinical Trials Information
2.3 Other Developmental Activities
2.4 Product Profile
3 Competitive Landscape (Marketed Therapies)
4 Competitive Landscape (Late-stage Emerging Therapies)
5 Latozinemab (AL001) Market Assessment
5.1 Market Outlook of Latozinemab (AL001) in Frontotemporal dementia
5.2 7MM Analysis
5.2.1 Market Size of Latozinemab (AL001) in the 7MM for Frontotemporal dementia
5.3 Country-wise Market Analysis
5.3.1 Market Size of Latozinemab (AL001) in the United States for Frontotemporal dementia
5.3.2 Market Size of Latozinemab (AL001) in Germany for Frontotemporal dementia
5.3.3 Market Size of Latozinemab (AL001) in France for Frontotemporal dementia
5.3.4 Market Size of Latozinemab (AL001) in Italy for Frontotemporal dementia
5.3.5 Market Size of Latozinemab (AL001) in Spain for Frontotemporal dementia
5.3.6 Market Size of Latozinemab (AL001) in the United Kingdom for Frontotemporal dementia
5.3.7 Market Size of Latozinemab (AL001) in Japan for Frontotemporal dementia
6 SWOT Analysis
7 Analysts' Views
For more information about this report visit https://www.researchandmarkets.com/r/m11swx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
